TY - JOUR
T1 - KRAS mutations affect prognosis of non-small-cell lung cancer patients treated with first-line platinum containing chemotherapy
AU - Marabese, Mirko
AU - Ganzinelli, Monica
AU - Garassino, Marina C.
AU - Shepherd, Frances A.
AU - Piva, Sheila
AU - Caiola, Elisa
AU - Macerelli, Marianna
AU - Bettini, Anna
AU - Lauricella, Calogero
AU - Floriani, Irene
AU - Farina, Gabriella
AU - Longo, Flavia
AU - Bonomi, Lucia
AU - Fabbri, M. Agnese
AU - Veronese, Silvio
AU - Marsoni, Silvia
AU - Broggini, Massimo
AU - Rulli, Eliana
PY - 2015
Y1 - 2015
N2 - KRAS mutations seem to indicate a poor outcome in Non-Small-Cell Lung Cancer (NSCLC) but such evidence is still debated. The aim of this planned ancillary study within the TAILOR trial was to assess the prognostic value of KRAS mutations in advanced NSCLC patients treated with platinum-based first-line chemotherapy. Patients (N = 540), enrolled in the study in 52 Italian hospitals, were centrally genotyped twice in two independent laboratories for EGFR and KRAS mutational status. Of these, 247 patients were eligible and included in the present study. The primary endpoint was overall survival (OS) according to KRAS mutational status in patients harboring EGFR wild-type. Sixty (24.3%) out of 247 patients harbored KRAS mutations. Median OS was 14.3 months and 10.6 months in wild-type and mutated KRAS patients, respectively (unadjusted Hazard Ratio [HR]=1.41, 95%Confidence Interval [CI]: 1.03-1.94 P = 0.032; adjusted HR=1.39, 95%CI: 1.00-1.94 P = 0.050). This study, with all consecutive patients genotyped, indicates that the presence of KRAS mutations has a mild negative impact on OS in advanced NSCLC patient treated with a firstline platinum-containing regimen.
AB - KRAS mutations seem to indicate a poor outcome in Non-Small-Cell Lung Cancer (NSCLC) but such evidence is still debated. The aim of this planned ancillary study within the TAILOR trial was to assess the prognostic value of KRAS mutations in advanced NSCLC patients treated with platinum-based first-line chemotherapy. Patients (N = 540), enrolled in the study in 52 Italian hospitals, were centrally genotyped twice in two independent laboratories for EGFR and KRAS mutational status. Of these, 247 patients were eligible and included in the present study. The primary endpoint was overall survival (OS) according to KRAS mutational status in patients harboring EGFR wild-type. Sixty (24.3%) out of 247 patients harbored KRAS mutations. Median OS was 14.3 months and 10.6 months in wild-type and mutated KRAS patients, respectively (unadjusted Hazard Ratio [HR]=1.41, 95%Confidence Interval [CI]: 1.03-1.94 P = 0.032; adjusted HR=1.39, 95%CI: 1.00-1.94 P = 0.050). This study, with all consecutive patients genotyped, indicates that the presence of KRAS mutations has a mild negative impact on OS in advanced NSCLC patient treated with a firstline platinum-containing regimen.
KW - First-line
KW - KRAS
KW - NSCLC
KW - Platinum
UR - http://www.scopus.com/inward/record.url?scp=84946055701&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84946055701&partnerID=8YFLogxK
U2 - 10.18632/oncotarget.5607
DO - 10.18632/oncotarget.5607
M3 - Article
AN - SCOPUS:84946055701
VL - 6
SP - 34014
EP - 34022
JO - Oncotarget
JF - Oncotarget
SN - 1949-2553
IS - 32
ER -